GSK to buy Boston Pharma's efimosfermin, a phase III─ready potential best─in─class specialty medicine to treat and ...
GSK plc and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, announced that they have entered into an agreement under which GSK will acquire Boston …